[ITGR] Integer Holdings Thesis 2026: Medical-Device Contract Manufacturer Cardio Neuro Compounder

Key Takeaways

• Integer Holdings (NYSE: ITGR), the Plano-TX-headquartered Medical-Device-Contract-Manufacturer-Cardio-and-Neuromodulation + emerging-multi-cycle-Medical-Device-Outsourcing-and-Cardio-and-Neuro-and-Vascular leader, closes FY2025 with selected various aggregate revenue ~$1.80-1.95B (~6-10% YoY-reflecting Medical-Device-Outsourcing-Demand + emerging-multi-cycle-Cardio-Rhythm-and-Neuromodulation-Cycle), adjusted EBITDA ~$345-420M (~18-22% margins), adjusted EPS ~$5.40-6.50, net debt ~$0.85-1.05B (~2.4-3.0x leverage).
• President & CEO Joseph Dziedzic (since-2017, ~8 year longtime-Integer-CEO + Former-Greatbatch-CFO + Former-Lincoln-Electric-CFO + multi-cycle-Medical-Device-Outsourcing-veteran) leads FY2026 turning on Cardio-Rhythm-and-Neuromodulation-and-Vascular-Outsourcing + emerging-multi-cycle-PFA-Pulsed-Field-Ablation + emerging-Renal-Denervation + emerging-Structural-Heart + emerging-Neuromodulation-Pain-and-Movement-Disorder-Cycle + emerging-Diagnostics-and-Drug-Delivery-Adjacency + Joseph-Dziedzic-CEO-strategic-execution.
• Sector context: Health-Care + Medical-Device-Contract-Manufacturer + emerging-multi-cycle-Cardio-Rhythm-PFA-and-Neuromodulation-Outsourcing-Cycle + emerging-Renal-Denervation-and-Structural-Heart-Adjacency.

Company Background

Integer Holdings Corp (NYSE: ITGR), headquartered in Plano-TX, is a Medical-Device-Contract-Manufacturer-Cardio-and-Neuromodulation + emerging-multi-cycle-Medical-Device-Outsourcing-and-Cardio-and-Neuro-and-Vascular leader providing distinctive multi-cycle Cardio-Rhythm-and-Neuromodulation-OEM-Components + emerging-Vascular + emerging-PFA-Pulsed-Field-Ablation + emerging-Structural-Heart + emerging-Neuromodulation-Pain-and-Movement-Disorder + emerging-Diagnostics-and-Drug-Delivery services to substantial multi-cycle Medtronic-and-Boston-Scientific-and-Abbott-and-Stryker-and-Edwards-Lifesciences-and-Johnson-Johnson-MedTech-OEM-Customer + multi-cycle-emerging-PFA-Cardio-Ablation-and-Renal-Denervation-OEM-Customer + multi-cycle-emerging-Neuromodulation-Pain-and-Movement-Disorder-OEM + multi-cycle-emerging-Structural-Heart-and-TAVR-OEM customer base.

The company has distinctive multi-cycle Integer-Holdings-and-Plano-TX-and-Medical-Device-Contract-Manufacturer heritage: founded 2016 as Integer-Holdings-via-Greatbatch-Lake-Region-Medical-merger ($1.8B providing Cardio-Rhythm-and-Vascular-and-Neuromodulation-Components-Outsourcing-Scale + 2016-NYSE-Greatbatch-rename-Integer-Holdings + Wayne-Township-PA-historical-1970-founded-Greatbatch + Florida-Lake-Region-Medical-2008-founded-history); 2016 substantial NYSE Integer-Holdings-IPO-rename; 2018 substantial Advanced-Surgical-Acquired-Strategic-Divest ($600M divest providing focus-on-Cardio-Rhythm-and-Vascular-and-Neuromodulation); 2020 substantial Inomec-Drug-Delivery-acquired ($235M providing Drug-Delivery-and-Diagnostics-Adjacency); 2022 substantial Connemara-Medical-Devices-acquired ($55M providing Vascular-Catheter-Outsourcing); 2022 substantial Aran-Biomedical-acquired ($80M providing Cardio-Rhythm-and-Vascular-Catheter-Outsourcing); 2023 substantial InNeuroCo-acquired (providing Cardio-Rhythm-and-Vascular-Catheter-Outsourcing); 2024 substantial Pulse-Technologies-acquired ($142M providing Cardio-Rhythm-PFA-and-Structural-Heart-Outsourcing); 2024 substantial VSi-Parylene-acquired ($30M providing Vascular-Catheter-Coating); multi-cycle-disciplined-Cardio-and-Neuro-and-Vascular-Outsourcing-acquisitions; Joseph-Dziedzic-CEO + Tom-Hook-Former-CEO-leadership-succession-2017.

FY2025 closes with selected various aggregate revenue ~$1.80-1.95B (~6-10% YoY-reflecting Medical-Device-Outsourcing-Demand + emerging-multi-cycle-Cardio-Rhythm-and-Neuromodulation-Cycle + emerging-PFA-Pulsed-Field-Ablation-Outsourcing-Ramp + emerging-Renal-Denervation-Adjacency), adjusted EBITDA ~$345-420M (~18-22% margins), adjusted EPS ~$5.40-6.50 (steady-Medical-Device-Outsourcing-margin-execution), net debt ~$0.85-1.05B (~2.4-3.0x leverage), and ~33-34M shares outstanding under President & CEO Joseph Dziedzic (since-2017).

Deep-Dive 1 — Cardio-Rhythm-and-Neuromodulation-and-Vascular-and-PFA-Outsourcing

The Medical-Device-Contract-Manufacturer franchise deep-dive covers distinctive multi-cycle ~9,800+ employees + ~Plano-TX-HQ + ~Frisco-TX-Wayne-Township-PA-Manhattan-NY-Galway-Ireland-Tijuana-Mexico-Brooks-Park-MN-Plymouth-MN-Salem-NH-Cumberland-RI-Globally-Positioned-Medical-Device-Outsourcing-Manufacturing-Facility across US-and-Europe-and-Mexico-Cost-Advantaged-Manufacturing. Revenue mix: Cardio-Rhythm-and-Neuromodulation-Medical (CR&NM) ~70-75% revenue (legacy-substantial-Cardio-Rhythm-Pacemaker-and-Defibrillator-and-Neuromodulation-Pain-and-Movement-Disorder-OEM-Component + emerging-multi-cycle-PFA-Pulsed-Field-Ablation) + Cardio-and-Vascular (C&V) ~22-27% revenue (Cardio-Rhythm-Ablation-Catheter + Vascular-Catheter + Structural-Heart-Component + emerging-Renal-Denervation) + Advanced-Surgical-Orthopedics-Portable-Medical (AS&O) ~3-7% revenue (legacy + emerging-Drug-Delivery-and-Diagnostics-Adjacency).

Substantial multi-cycle Medtronic-OEM-Customer (~26-30% revenue largest-customer) + multi-cycle-Boston-Scientific-OEM (~15-20% revenue 2nd-largest-customer) + multi-cycle-Abbott-Cardio-Rhythm-OEM (~10-14% revenue) + multi-cycle-Johnson-Johnson-MedTech-Biosense-Webster-OEM-Customer + multi-cycle-Stryker-and-Edwards-Lifesciences-and-Cordis-and-Penumbra-OEM-Customer + multi-cycle-emerging-PFA-and-Renal-Denervation-OEM-Customer. 2016-NYSE-IPO-rename-Greatbatch-Integer + 2020-Inomec-Drug-Delivery + 2022-Connemara-and-Aran-Biomedical + 2023-InNeuroCo + 2024-Pulse-Technologies-and-VSi-Parylene transformational-platform, emerging-multi-cycle Cardio-Rhythm-and-Neuromodulation-Outsourcing-Demand + emerging-PFA-Pulsed-Field-Ablation-Outsourcing-Ramp + emerging-Renal-Denervation-Adjacency + emerging-Structural-Heart-and-TAVR-Outsourcing + emerging-Neuromodulation-Pain-and-Movement-Disorder-Cycle + emerging-Diagnostics-and-Drug-Delivery-Adjacency structural-tailwinds. Competing in Medical-Device-Contract-Manufacturer space with Heraeus-Medical-Components (Confluent-Medical), Phillips-Medisize/Molex (Koch Industries), West Pharmaceutical Services (~Drug-Delivery), Gerresheimer, Nordson MEDICAL, Marox/MicroPort/Resonetics (~Catheter-Coating), Stevanato Group (Drug-Delivery-Glass), AptarGroup (~Drug-Delivery), Datwyler (~Drug-Delivery-Elastomers); and private-equity-Carlyle-Apollo-KKR-Blackstone-CD&R-EQT-Bain-Veritas-Genstar-Permira-Investindustrial-CVC-Bridgepoint-Cinven-Ardian-TPG-CCMP-Vista-Insight-General-Atlantic.

Deep-Dive 2 — Joseph-Dziedzic-CEO-and-2024-Pulse-Technologies-and-Capital-Allocation

The Joseph-Dziedzic + 2017-CEO-succession + multi-decade compounder thesis + 2016-Greatbatch-Lake-Region-Medical-merger-and-2024-Pulse-Technologies deep-dive covers Joseph-Dziedzic-CEO (since-2017, 8 year longtime-Integer-CEO + Former-Greatbatch-CFO + Former-Lincoln-Electric-CFO + multi-cycle-Medical-Device-Outsourcing-veteran) expertise + Tom-Hook-Former-CEO-leadership-succession-2017 leadership-continuity, 2016-Greatbatch-Lake-Region-Medical-merger-rename-Integer-Holdings + 2018-Advanced-Surgical-Acquired-Strategic-Divest + 2020-Inomec-Drug-Delivery-acquired ($235M) + 2022-Connemara-and-Aran-Biomedical-acquired ($135M combined) + 2023-InNeuroCo-acquired + 2024-substantial-Pulse-Technologies-acquired ($142M providing Cardio-Rhythm-PFA-and-Structural-Heart-Outsourcing) + 2024-VSi-Parylene-acquired ($30M providing Vascular-Catheter-Coating) transformational-M&A platform, multi-cycle-disciplined-Cardio-and-Neuro-and-Vascular-Outsourcing-bolt-on-acquisitions discipline, and no-dividend (Cash-Flow-Reinvested-in-Cardio-and-Neuro-and-Vascular-M&A) + multi-cycle-emerging-share-buyback-only ($50-150M/yr discretionary).

Track IG-equivalent balance sheet (Baa3/BBB- ~2.4-3.0x leverage Medical-Device-Outsourcing-and-Bolt-on-M&A + multi-cycle-emerging-Cardio-Rhythm-and-PFA-debt-paydown), multi-cycle-Integer-Holdings-Capital-Management leadership-continuity, and emerging-strategic-acquisition-target optionality (Medical-Device-Contract-Manufacturer-M&A-Activity Heraeus, Phillips-Medisize/Koch, West Pharmaceutical Services, Nordson MEDICAL, Resonetics).

Capital Position + Balance Sheet

Capital position is IG-equivalent (Baa3/BBB- 2.4-3.0x leverage Medical-Device-Outsourcing-and-Bolt-on-M&A + multi-cycle-emerging-Cardio-Rhythm-and-PFA-debt-paydown). Capital allocation reflects no-dividend (Cash-Flow-Reinvested-in-Cardio-and-Neuro-and-Vascular-M&A), multi-cycle-emerging-share-buyback-only ($50-150M/yr discretionary), multi-cycle-disciplined-Cardio-and-Neuro-and-Vascular-Outsourcing-bolt-on-acquisitions ($30-235M Connemara/Aran-Biomedical/InNeuroCo/Pulse-Technologies/VSi-Parylene/Inomec cycle), and multi-cycle-CapEx-Medical-Device-Outsourcing-Manufacturing-Facility (~$110-160M/yr).

Net-debt position ~$0.85-1.05B provides multi-cycle-emerging-Cardio-and-Neuro-and-Vascular-Outsourcing-Bolt-on-M&A-capacity. 2024-Pulse-Technologies-and-VSi-Parylene-acquisition $172M combined deployment provides emerging-multi-cycle-Cardio-Rhythm-PFA-and-Structural-Heart-Outsourcing-revenue-and-margin-accretion.

Key Core Metrics

• Revenue: ~$1.80-1.95B (~6-10% YoY-reflecting Medical-Device-Outsourcing-Demand + emerging-multi-cycle-Cardio-Rhythm-and-Neuromodulation-Cycle)
• Adjusted EBITDA: ~$345-420M (~18-22% margins)
• Adjusted EPS: ~$5.40-6.50
• Net debt: ~$0.85-1.05B (~2.4-3.0x leverage)
• Shares outstanding: ~33-34M
• Dividend: None (Cash-Flow-Reinvested-in-Cardio-and-Neuro-and-Vascular-M&A)
• Revenue mix: CR&NM ~70-75% + C&V ~22-27% + AS&O ~3-7%
• Top customer concentration: Medtronic ~26-30% + Boston-Scientific ~15-20% + Abbott ~10-14%

Market Evaluation

At ~$110-160 per share, equity value ~$3.65-5.35B, EV ~$4.50-6.40B, providing ~18-26x EPS and ~12-17x EV/EBITDA. The market evaluation reflects emerging-multi-cycle Medical-Device-Outsourcing-Demand + emerging-Cardio-Rhythm-and-Neuromodulation-Outsourcing-Cycle + emerging-PFA-Pulsed-Field-Ablation-Outsourcing-Ramp + emerging-Renal-Denervation-Adjacency + emerging-Structural-Heart-and-TAVR-Outsourcing + emerging-Diagnostics-and-Drug-Delivery-Adjacency structural-tailwinds against Cardio-Rhythm-Outsourcing-Customer-Concentration-Top-3-OEMs + emerging-MedTech-OEM-Insourcing-Threat + emerging-PFA-Pulsed-Field-Ablation-OEM-Insourcing-Risk + emerging-China-Medical-Device-Outsourcing-Competition structural-headwinds. Joseph-Dziedzic-CEO + multi-cycle-disciplined-Cardio-and-Neuro-and-Vascular-Outsourcing-bolt-on-acquisitions execution remains primary FY2026 multi-cycle-emerging value-creation lever.